Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Safaa M. Ramadan, PhD MD, Giusy Ceparano, MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Vincenzo Bagnardi, Eleonora Pagan, Daniela Gottardi, MD, Stefano Fiori, MD, Rita Passerini, Tommaso Radice, MD, Giuseppe Saglio, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1522.

https://doi.org/10.1182/blood-2019-132237

Published: 2019

Journal Articles

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Enrico Derenzini, MD PhD, Angela Gueli, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Simona Sammassimo, MD, Federica Gigli, MD, Niccolo' Frungillo, MD, Riccardo Bruna, MD, Alberto Agazzi, MD, Alberto De Crescenzo, MD, Rocco Pastano, MD, Laura L Travaini, MD, Chiara Grana, MD, Laszlo Daniele, MD, William Arcese, Corrado Tarella, MD

Blood (2016) 128 (22): 3003.

https://doi.org/10.1182/blood.V128.22.3003.3003

Published: 2016

Journal Articles

Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells As Graft Source for Non-Myeloablative Haploidentical Transplantation: Fast Engraftment, No Evidence of Graft Rejection, and Low Incidence of Graft-Versus-Host Disease

Rocco Pastano, MD, Giovanna Andreola, MD, Federica Gigli, MD, Simona Sammassimo, MD, Mara Negri, Liptrott Jayne Sarah, Corrado Tarella, MD

Blood (2015) 126 (23): 1924.

https://doi.org/10.1182/blood.V126.23.1924.1924

Published: 2015

Journal Articles

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Anna Vanazzi, MD, Alessandra Alietti, MD, Alberto Agazzi, MD, Mara Negri, Maria Teresa Lionetti, Aleksandra Babic, Davide Radice, Luca Nassi, MD, Simona Sammassimo, MD, Cristina Rabascio, Pierluigi Antoniotti, Lara Roveda, Bruno Lucchetti, Tiziana Suardi, Alessio Piredda, Liliana Calabrese, Giovanni Martinelli, MD, Daniele Laszlo, MD

Blood (2009) 114 (22): 3210.

https://doi.org/10.1182/blood.V114.22.3210.3210

Published: 2009

Journal Articles

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Simona Bassi, MD, Luca Nassi, MD, Giancarlo Pruneri, MD, Simona Sammassimo, MD, Paola Bertazzoni, MD, Federica Gigli, MD, Anna Vanazzi, MD, Emilia Cocorocchio, MD, Patrizia Mancuso, Cristina Rabascio, Maria Teresa Lionetti, Daniele Laszlo, MD, Giovanni Martinelli, MD

Blood (2009) 114 (22): 3754.

https://doi.org/10.1182/blood.V114.22.3754.3754

Published: 2009

Journal Articles

Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.

Daniele Laszlo, MD, Cristina Rabascio, DSc, Giovanna Andreola, MD, Luca Saronni, DSc, Liliana Calabrese, DSc, Luigi Rigacci, MD, Alberto Fabbri, MD, Antonello Pinto, MD, Ferdinando Frigeri, MD, Atto Billio, MD, Graziella Pinotti, MD, Simona Sammassimo, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 1357.

https://doi.org/10.1182/blood.V110.11.1357.1357

Published: 2007

Journal Articles

Phase II Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen as Induction Therapy Plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients.

Maria Teresa Pirrotta, MD, Monica Bocchia, MD, Alessandro Bucalossi, MD, Marzia Defina, MD, Francesco Forconi, MD, Simona Sammassimo, MD, Francesco Lauria, MD

Blood (2005) 106 (11): 4613.

https://doi.org/10.1182/blood.V106.11.4613.4613

Published: 2005

NARROW

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells As Graft Source for Non-Myeloablative Haploidentical Transplantation: Fast Engraftment, No Evidence of Graft Rejection, and Low Incidence of Graft-Versus-Host Disease

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.

Phase II Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen as Induction Therapy Plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only